Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook > Product Catalogue >API >Hormones and the Endocrine System >Pancreatic hormone and blood sugar regulation >Liraglutide

Liraglutide

Liraglutide Structure
  • ₹0
  • Product name: Liraglutide
  • CAS: 204656-20-2
  • MF: C172H265N43O51
  • MW: 3751.202
  • EINECS:810-818-7
  • MDL Number:MFCD31689263
  • Synonyms:Liraglutide;Glycine, L-histidyl-L-alanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alpha-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(N-(1-oxohexadecyl)-L-gamma-glutamyl)-L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-;Liraglutida;Liraglutida [inn-spanish];Liraglutide [usan:inn];Liraglutidum;Liraglutidum [inn-latin];N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glp-1-(7-37)-peptide
Manufacturer Product number Product description Packaging Price Updated Buy

Properties

Melting point :>182°C (dec.)
storage temp. :Refrigerator
solubility :DMSO (Slightly), Water (Slightly)
form :Solid
color :White to Off-White
Sequence :H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-
InChIKey :YSDQQAXHVYUZIW-VTFFJMQZNA-N

Safety Information

Symbol(GHS): GHS hazard pictograms
Signal word: Warning
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H315 Causes skin irritation Skin corrosion/irritation Category 2 Warning GHS hazard pictograms P264, P280, P302+P352, P321,P332+P313, P362
H319 Causes serious eye irritation Serious eye damage/eye irritation Category 2A Warning GHS hazard pictograms P264, P280, P305+P351+P338,P337+P313P
H335 May cause respiratory irritation Specific target organ toxicity, single exposure;Respiratory tract irritation Category 3 Warning GHS hazard pictograms
Precautionary statements:
P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

Description

Approaches to treating type 2 diabetes mellitus (T2DM), a disease marked by islet cell dysfunction and insulin resistance, involve the use of secretagogues, which boost insulin secretion by the pancreas, sensitizers, which increase target organ sensitivity to insulin, and agents that slow down glucose absorption from the gastrointestinal tract. Liraglutide, a GLP-1 receptor agonist, has a 97% homology to GLP-1, featuring two amino acid changes and an added fatty acid side chain. The lysine in position 34 is replaced with arginine, and the lysine in position 26 is modified with a C16 acyl chain via a glutamoyl spacer. Liraglutide's resistance to DPP-4 degradation stems from its tendency to form micelles and bind to albumin. As a once-daily treatment, it is more convenient than its predecessor, exenatide, which necessitates two daily subcutaneous injections. Liraglutide can be used alongside metformin or a sulfonylurea in patients with inadequate glycemic control on either monotherapy or combined dual therapy. It is also approved for use in combination with metformin and a thiazolidinedione for patients with insufficient glycemic control on dual therapy. Liraglutide exhibits a binding potency of 61 pM (EC50= 55 pM for GLP-1) for the cloned human GLP-1 receptor.

Related product price